Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of SYD985 plus niraparib in HER2-expressing advanced solid tumors
NL-OMON52764Phase 1Active, not recruiting
- Sponsor
- Byondis
- Start
- May 2021
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of trastuzumab duocarmazine and niraparib in Nonhematologic neoplasms, breast cancer, ovarian cancer and 2 more (2 arms), sponsored by Byondis. Primary endpoints: Incidence of dose-limiting toxicity and Objective response rate. Started May 2021; status: active, not recruiting.
02
Drugs
trastuzumab duocarmazineniraparib
03
Conditions
Nonhematologic neoplasmsbreast cancerovarian cancerendometrial cancer (EC)carcinosarcoma
Beyond the preview
Go deeper on NL-OMON52764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52764.